Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.51 |
| ▸ | AR | P10275 | 4/20 | 0.51 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25546823 | 0.85 | PARP1 (0.51) | PARP1ARENPP1LMNACYP3A4 | |
| SCHEMBL25546738 | 0.85 | PARP1 (0.71) | PARP1ARENPP1LMNACYP3A4 | |
| SCHEMBL24000595 | 0.85 | ENPP1 (0.69) | PARP1ARENPP1LMNACYP3A4 | |
| SCHEMBL24000680 | 0.85 | PARP1 (0.63) | PARP1ARCYP3A4CYP2C9TSHR | |
| SCHEMBL25546766 | 0.84 | ENPP1 (0.55) | PARP1ARENPP1LMNACYP3A4 | |
| Hydrochloric Acid SCHEMBL30088725 | 0.83 | ENPP1 (0.67) | PARP1ARENPP1LMNACYP3A4 | |
| SCHEMBL12955341 | 0.82 | AR (0.77) | PARP1ARENPP1LMNACYP3A4 | |
| Hydrochloric Acid SCHEMBL30088838 | 0.81 | AR (0.74) | PARP1ARENPP1LMNACYP3A4 | |
| SCHEMBL25546799 | 0.79 | ENPP1 (0.78) | PARP1ARENPP1LMNACYP3A4 | |
| SCHEMBL4697722 | 0.79 | LMNA (0.68) | PARP1ARENPP1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159469-A1 | NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF | TXINNO BIOSCIENCE INC. (KR) | 2023-05-25 | — | — | US | disclosed |
| WO-2021225407-A1 | NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE INHIBITORY ACTIVITY, AND USE THEREOF | 주식회사 티씨노바이오사이언스 (KR) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159469-A1 | NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF | ENPP1, ENPP3, PPA1 | PARP1 2763/4885AR 4407/4885ENPP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.